Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

iShares Nasdaq Biotechnology ETF (IBB)

Delayed Data
As of Apr 29
 -7.32 / -2.66%
Today’s Change
Today|||52-Week Range

Investment Objective

The investment seeks to track the investment results of the NASDAQ Biotechnology Index, which contains securities of NASDAQ  listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by NASDAQ OMX. The fund generally invests at least 90% of its assets in securities of the index and in depositary receipts representing securities of the index. It may invest the remainder of its assets in certain futures, options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.


1 month+4.56% 3 years+15.75%
3 months+0.38% 5 years+20.25%
1 year-22.14% Since inception+6.84%
Data through 04/30/2016

Quote Details

Previous close$275.27
Open day’s range265.78 – 274.89
Net asset value (NAV)268.14 (04/29/2016)
Daily volume3,007,502
Average volume (3 months)2,430,253
Data as of 4:00pm ET, 04/29/2016

Peer Comparisonvs. Health ETFs

Performance 5-yr return+20.25%+15.78%
Expense Gross exp ratio0.48%0.47%
Risk 5 year sharpe ratio1.011.00
Net assets$6.4B$1.2B
Average market cap$14.1B$28.1B
Average P/E20.422.4
Dividend / Share--0.22%


XLV Health Care Select Sector SPDR® Fund
VHT Vanguard Health Care Index Fund ETF Shar...
RYH Guggenheim S&P 500® Equal Weight Health...


Top 5 Sectors
Portfolio weighting
Healthcare 99.91%
Business service 0.09%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
AMGN Amgen8.24%
GILD Gilead Sciences8.23%
BIIB Biogen7.84%
CELG Celgene7.76%
REGN Regeneron Pharmaceuticals7.05%
ILMN Illumina Inc4.22%
MYL Mylan NV4.02%
ALXN Alexion Pharmaceuticals Inc3.86%
VRTX Vertex Pharmaceuticals Inc3.63%
INCY Incyte Corp2.76%

Partner Offers